Table 3

Univariate linear regression on the increase in pVO2 after AVR

Explanatory variableβSEp Value
Age (per year)
Male vs female−3.475.250.51
Atrial fibrillation−8.745.660.13
Mean gradient (per mm Hg)0.370.150.02
Mean gradient<40 mm Hg−16.905.430.004
AVAI (per 0.1 cm2/m2)−3.702.030.078
AVAI<0.4 cm2/m28.294.70.089
Sa (per 1 cm/s)2.351.940.23
E/e’ (per unit)−0.020.480.97
Ln BNP/ULN of BNP−4.902.200.033
pVO2 (per mL/kg)
Percentage of predicted pVO2 (per %)
Percentage of predicted pO2 pulse (per 1%)
pO2 pulse < median value (98% of predicted)−1.954.860.69
On β-blocker−
TAVR (vs SAVR)−7.725.570.18
On β-blocker−10.474.540.027
Change in Hb (per mmol/l)9.393.690.016
Ln BNP/ULN of BNP−5.171.910.011
Ln days in hospital−8.964.420.051
Mean gradient (per mm Hg)0.560.480.25
Sa (per 1 cm/s)2.061.440.16
Change in Sa (per cm/s)2.322.280.32
E/e’ (per unit)−0.700.400.093
Change in E/e’−0.690.420.11
  • AVAI, aortic valve area index; AVR, aortic valve replacement; BNP>ULN, brain natriuretic peptide > upper level of normal; COPD, chronic obstructive pulmonary disease; E, early diastolic inflow velocity; e’, early lateral mitral annulus velocity; pVO2, peak oxygen consumption; Sa, peak systolic tissue velocity; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.